Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

PURPOSE: Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS: ATALANTE/ENGOT-ov29 (Clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtz, Jean-Emmanuel, Pujade-Lauraine, Eric, Oaknin, Ana, Belin, Lisa, Leitner, Katharina, Cibula, David, Denys, Hannelore, Rosengarten, Ora, Rodrigues, Manuel, de Gregorio, Nikolaus, Martinez García, Jeronimo, Petru, Edgar, Kocián, Roman, Vergote, Ignace, Pautier, Patricia, Schmalfeldt, Barbara, Gaba, Lydia, Polterauer, Stephan, Mouret Reynier, Marie-Ange, Sehouli, Jalid, Churruca, Cristina, Selle, Frédéric, Joly, Florence, D'Hondt, Véronique, Bultot-Boissier, Émilie, Lebreton, Coriolan, Lotz, Jean-Pierre, Largillier, Rémy, Heudel, Pierre-Etienne, Heitz, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602539/
https://www.ncbi.nlm.nih.gov/pubmed/37643382
http://dx.doi.org/10.1200/JCO.23.00529

Ejemplares similares

Ejemplares similares